Medicine and Dentistry
Atrial Fibrillation
100%
Patient
71%
Apoplexy
38%
Inpatient
38%
Antithrombotic
23%
Anticoagulation
15%
Association
14%
Therapeutic Procedure
14%
Cohort Analysis
13%
Thromboembolism
12%
Cardiovascular System
12%
Vitamin K Antagonist
10%
Mortality
10%
Age
10%
Follow up
9%
Heart Failure
9%
Brain Ischemia
9%
Death
9%
Warfarin
8%
Hazard Ratio
8%
Analysis
8%
CHA2DS2-VASc Score
8%
Major Bleeding
7%
Bleeding
7%
Heart Rhythm
7%
Combination Therapy
6%
Incidence
6%
Venous Thromboembolism
6%
Anticoagulant Therapy
6%
Systematic Review
5%
Cardiac Dysrhythmia
5%
Cardiovascular Disease
5%
Hypertension
5%
Meta-Analysis
5%
Female
5%
Percutaneous Coronary Intervention
5%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
95%
Anticoagulant Agent
44%
Warfarin
24%
Antivitamin K
22%
Bleeding
17%
Cohort Study
15%
Dabigatran
13%
Thromboembolism
12%
Brain Ischemia
10%
Mortality
9%
Rivaroxaban
9%
Apixaban
8%
Venous Thromboembolism
7%
Death
7%
Brain Hemorrhage
6%
Embolism
6%
Incidence
6%
Heart Failure
5%
Nursing and Health Professions
Atrial Fibrillation
57%
Patient
25%
Inpatient
12%
Anticoagulant Agent
11%
Warfarin
8%
Combination Therapy
8%
Anticoagulation
7%
Control
7%
Confidence Interval
6%
Cohort Analysis
6%
Antivitamin K
6%
Thromboembolism
6%
Heart Failure
5%
Mortality
5%
Prevention
5%
Bleeding
5%
Hazard Ratio
5%